CD19 and acute lymphoblastic leukemia: With excellent response rates in CD19 positive cancers, a relevant proportion of patients may experience a sustained complete response (which can be considered a cure from the primary disease) in 40% of B-ALL (4, 87) and DLBCL patients (88, 89), whereas in CLL the sustained complete response rate is 20% (90).